Bioventus Inc. (BVS) NASDAQ
$2.10 -0.10 (-4.54%)
Market Cap: $129.49M
As of 02/03/23 04:00 PM EST. Market closed.
Bioventus Inc. (BVS) NASDAQ
$2.10 -0.10 (-4.54%)
Market Cap: $129.49M
As of 02/03/23 04:00 PM EST. Market closed.
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and ... read more
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. read less
Open in: 
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| D'Adamio Anthony | SVP & General Counsel | Apr 04, 2022 | Sale | $11.19 | 16,016 | 179,238 | 40,132 | Apr 05, 2022, 09:16 PM |
| Nosenzo John | Chief Commercial Officer | Apr 04, 2022 | Sale | $11.12 | 65,963 | 733,502 | 83,932 | Apr 05, 2022, 09:14 PM |
| Pavesio Alessandra | SVP & Chief Science Officer | Apr 04, 2022 | Sale | $11.17 | 32,997 | 368,425 | 148,309 | Apr 05, 2022, 09:09 PM |
| Pavesio Alessandra | SVP & Chief Science Officer | Feb 14, 2022 | Sale | $11.99 | 433 | 5,192 | 119,830 | Feb 16, 2022, 06:29 PM |
| D'Adamio Anthony | SVP & General Counsel | Feb 14, 2022 | Sale | $11.99 | 1,294 | 15,513 | 18,672 | Feb 15, 2022, 09:31 PM |
| Anglum Gregory O. | SVP & CFO | Feb 14, 2022 | Sale | $11.99 | 1,294 | 15,518 | 55,013 | Feb 15, 2022, 09:27 PM |
| Nosenzo John | Chief Commercial Officer | Feb 14, 2022 | Sale | $11.99 | 534 | 6,401 | 43,370 | Feb 15, 2022, 09:17 PM |
| Pavesio Alessandra | SVP & CHIEF SCIENCE OFFICER | Feb 10, 2022 | Option Exercise | $12.88 | 73,915 | 952,025 | 118,793 | Feb 14, 2022, 08:43 PM |
| Nosenzo John | CHIEF COMMERCIAL OFFICER | Feb 10, 2022 | Option Exercise | $12.88 | 24,205 | 311,760 | 42,434 | Feb 14, 2022, 08:41 PM |
| D'Adamio Anthony | SVP & General Counsel | Feb 10, 2022 | Option Exercise | $12.88 | 6,599 | 84,995 | 15,566 | Feb 14, 2022, 08:37 PM |
| Anglum Gregory O. | SVP & CFO | Feb 10, 2022 | Option Exercise | $12.88 | 19,674 | 253,401 | 51,907 | Feb 14, 2022, 08:35 PM |
| Reali Kenneth Michael | CHIEF EXECUTIVE OFFICER | Sep 09, 2021 | Buy | $14.81 | 1,800 | 26,658 | 11,175 | Sep 10, 2021, 09:22 AM |
| Anglum Gregory O. | SVP & General Counsel | Feb 11, 2021 | Buy | $13.00 | 6,000 | 78,000 | 6,000 | Apr 05, 2021, 04:35 PM |
| Owner | Relationship | Date | Value($) |
| D'Adamio Anthony | SVP & General Counsel | 04/04/2022 | 179,238 |
| Nosenzo John | Chief Commercial Officer | 04/04/2022 | 733,502 |
| Pavesio Alessandra | SVP & Chief Science Officer | 04/04/2022 | 368,425 |
| Pavesio Alessandra | SVP & Chief Science Officer | 02/14/2022 | 5,192 |
| D'Adamio Anthony | SVP & General Counsel | 02/14/2022 | 15,513 |
| Anglum Gregory O. | SVP & CFO | 02/14/2022 | 15,518 |
| Nosenzo John | Chief Commercial Officer | 02/14/2022 | 6,401 |
| Pavesio Alessandra | SVP & CHIEF SCIENCE OFFICER | 02/10/2022 | 952,025 |
| Nosenzo John | CHIEF COMMERCIAL OFFICER | 02/10/2022 | 311,760 |
| D'Adamio Anthony | SVP & General Counsel | 02/10/2022 | 84,995 |
| Anglum Gregory O. | SVP & CFO | 02/10/2022 | 253,401 |
| Reali Kenneth Michael | CHIEF EXECUTIVE OFFICER | 09/09/2021 | 26,658 |
| Anglum Gregory O. | SVP & General Counsel | 02/11/2021 | 78,000 |
Period of Report: 10/01/2022
10-K/10-Q Filings: View